Send to

Choose Destination
Bioorg Med Chem Lett. 2009 Jan 1;19(1):27-30. doi: 10.1016/j.bmcl.2008.11.033. Epub 2008 Nov 14.

Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors.

Author information

Department of Chemistry, Cardiovascular and Urogenital Center of Excellence in Drug Discovery, GlaxoSmithKline, UW2430, King of Prussia, PA 19406, USA.


Endothelial lipase (EL) activity has been implicated in HDL catabolism, vascular inflammation, and atherogenesis, and inhibitors are therefore expected to be useful for the treatment of cardiovascular disease. Sulfonylfuran urea 1 was identified in a high-throughput screening campaign as a potent and non-selective EL inhibitor. A lead optimization effort was undertaken to improve potency and selectivity, and modifications leading to improved LPL selectivity were identified. Radiolabeling studies were undertaken to establish the mechanism of action for these inhibitors, which were ultimately demonstrated to be irreversible inhibitors.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center